Osteoporosis
Conditions
Brief summary
This study will assess the effectiveness of the allogeneic mesenchymal cell from umbilical cord in improving the quality and quantity of spinal density of osteoporosis patients proven by the results of Bone Mass Density (BMD) examination compared to baseline and evaluate improvement of quality of pain with visual analog scale (VAS).
Detailed description
Currently, preventive and therapeutic strategies for osteoporosis patients are based on calcium and vitamin D supplementation, the use of pharmacological agents that inhibit bone resorption such as bisphosphonates, and sometimes calcitonin. Although bisphosphonates have been found to reduce osteoporosis, clinical use for these drugs has been limited because of its potential to produce serious side effects, such as mandibular osteonecrosis and atypical femoral fractures. Therefore, new therapeutic strategies for osteoporosis are needed. This study will assess the effectiveness of the allogeneic mesenchymal cell from umbilical cord. Patients who have received mesenchymal stem cell therapy (MSC) are expected to have positive effects such as reduced pain sensation in the back assessed by Visual Analog Scale (VAS), improvement in the range of motion (ROM), improving the quality of osteoporosis patients's bone proven by the results of Bone Mass Density (BMD) and improvement in patients' quality of life.
Interventions
DRUGMesenchymal Stem Cell
Mesenchymal Stem Cell + NaCl 0,9% 2ml
Sponsors
Ahmad Jabir Rahyussalim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male patients older than 50 yrs old. 2. Female patients older than 40 years old. 3. Patients enrolled in Cipto Mangunkusumo Hospital with osteoporosis confirmed by BMD test. 4. Patients with no history of autoimun disease (SLE, Addison's disease, Chron's disease) and other diseases related to osteoporosis. 5. Patients with no history of consuming drug related osteoporosis. 6. No active infection confirmed by HbsAg, HIV, CMV, Rubella and Toxoplasma examination. 7. Agree to participate the study by signing informed consent form.
Exclusion criteria
1. Patients with autoimun diesasde (SLE, Addison's diesase, Chron's disease and other osteoporosis related disease. 2. Patients under immunosuppressive, anticoagulant or corticosteroid treatment. 3. Paralysis patients after surgical treatment 4. Patients under 20 years old 5. Declined to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bone Mass Density (BMD) | 6 months | Improvement of spinal density in osteoporosis patients proven by the results of Bone Mass Density (BMD). 1. Above Standard Deviation (SD) (-1) means normal 2. Between SD (-1) and (-2.5) is classified as osteopenia. Osteopenia is a condition when bone density is lower than the average, but not as low as osteoporosis. 3. Below SD (-2.5) is categorized as osteoporosis. The numbers are expected to be higher after MSC implantation. |
| Visual Analog Scale (VAS) | 6 months | Evaluates pain quality using Visual Analog Scale (VAS) from 0 - 10. Zero is no pain at all, one is the the least pain and ten is the most painful. The numbers are expected to be lower after MSC implantation. |
Countries
Indonesia
Contacts
Primary ContactAhmad Jabir Rahyussalim
Backup ContactTri Kurniawati, S.Si
Outcome results
None listed